Literature DB >> 16601077

Assessment of contractility of purified smooth muscle cells derived from embryonic stem cells.

Sanjay Sinha1, Brian R Wamhoff, Mark H Hoofnagle, James Thomas, Ronald L Neppl, Thomas Deering, Brian P Helmke, Douglas K Bowles, Avril V Somlyo, Gary K Owens.   

Abstract

The aims of this study were to develop a method for deriving purified populations of contractile smooth muscle cells (SMCs) from embryonic stem cells (ESCs) and to characterize their function. Transgenic ESC lines were generated that stably expressed a puromycin-resistance gene under the control of either a smooth muscle alpha-actin (SMalphaAlpha) or smooth muscle-myosin heavy chain (SM-MHC) promoter. Negative selection, either overnight or for 3 days, was then used to purify SMCs from embryoid bodies. Purified SMCs expressed multiple SMC markers by immunofluorescence, immunoblotting, quantitative reverse transcription-polymerase chain reaction, and flow cytometry and were designated APSCs (SMalphaAlpha-puromycin-selected cells) or MPSCs (SM-MHC-puromycin-selected cells), respectively. Both SMC lines displayed agonist-induced Ca(2+) transients, expressed functional Ca(2+) channels, and generated contractile force when aggregated within collagen gels and stimulated with vasoactive agonists, such as endothelin-1, or in response to depolarization with KCl. Importantly, subcutaneous injection of APSCs or MPSCs subjected to 18 hours of puromycin selection led to the formation of teratomas, presumably due to residual contamination by pluripotent stem cells. In contrast, APSCs or MPSCs subjected to prolonged puromycin selection for 3 days did not form teratomas in vivo. These studies describe for the first time a method for generating relatively pure populations of SMCs from ESCs which display appropriate excitation and contractile responses to vasoactive agonists. However, studies also indicate the potential for teratoma development in ESC-derived cell lines, even after prolonged differentiation, highlighting the critical requirement for efficient methods of separating differentiated cells from residual pluripotent precursors in future studies that use ESC derivatives, whether SMC or other cell types, in tissue engineering applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601077     DOI: 10.1634/stemcells.2006-0002

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  30 in total

1.  Derivation of functional smooth muscle cells from multipotent human hair follicle mesenchymal stem cells.

Authors:  Jin Yu Liu; Hao Fan Peng; Siddhita Gopinath; Jun Tian; Stelios T Andreadis
Journal:  Tissue Eng Part A       Date:  2010-08       Impact factor: 3.845

2.  Transdifferentiation of human endothelial progenitors into smooth muscle cells.

Authors:  HaYeun Ji; Leigh Atchison; Zaozao Chen; Syandan Chakraborty; Youngmee Jung; George A Truskey; Nicolas Christoforou; Kam W Leong
Journal:  Biomaterials       Date:  2016-02-03       Impact factor: 12.479

3.  Human amniotic fluid stem cell differentiation along smooth muscle lineage.

Authors:  Marco Ghionzoli; Andrea Repele; Laura Sartiani; Giulia Costanzi; Astrid Parenti; Valentina Spinelli; Anna L David; Massimo Garriboli; Giorgia Totonelli; Jun Tian; Stelios T Andreadis; Elisabetta Cerbai; Alessandro Mugelli; Antonio Messineo; Agostino Pierro; Simon Eaton; Paolo De Coppi
Journal:  FASEB J       Date:  2013-08-30       Impact factor: 5.191

4.  Evidence for self-maintaining pluripotent murine stem cells in embryoid bodies.

Authors:  Wael A Attia; Osama M Abd El Aziz; Dimitry Spitkovsky; John A Gaspar; Peter Dröge; Frank Suhr; Davood Sabour; Johannes Winkler; Kesavan Meganathan; Smita Jagtap; Markus Khalil; Jürgen Hescheler
Journal:  Stem Cell Rev Rep       Date:  2014-02       Impact factor: 5.739

5.  Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells.

Authors:  Jeffrey J Ross; Zhigang Hong; Ben Willenbring; Lepeng Zeng; Brett Isenberg; Eu Han Lee; Morayma Reyes; Susan A Keirstead; E Kenneth Weir; Robert T Tranquillo; Catherine M Verfaillie
Journal:  J Clin Invest       Date:  2006-11-09       Impact factor: 14.808

6.  Application of induced pluripotent stem cells to model smooth muscle cell function in vascular diseases.

Authors:  HaYeun Ji; Hye Sung Kim; Hae-Won Kim; Kam W Leong
Journal:  Curr Opin Biomed Eng       Date:  2017-03-22

7.  A comparison of murine smooth muscle cells generated from embryonic versus induced pluripotent stem cells.

Authors:  Chang-Qing Xie; Huarong Huang; Sheng Wei; Long-Sheng Song; Jifeng Zhang; Raquel P Ritchie; Liangbiao Chen; Ming Zhang; Y Eugene Chen
Journal:  Stem Cells Dev       Date:  2009-06       Impact factor: 3.272

Review 8.  Adipose derived stem cells and smooth muscle cells: implications for regenerative medicine.

Authors:  Jennifer Anne de Villiers; Nicolette Houreld; Heidi Abrahamse
Journal:  Stem Cell Rev Rep       Date:  2009-08-11       Impact factor: 5.739

9.  Xeno-free culture of human spermatogonial stem cells supported by human embryonic stem cell-derived fibroblast-like cells.

Authors:  Bin Chen; Yu-Bin Wang; Zhi-Ling Zhang; Wei-Liang Xia; Hong-Xiang Wang; Zu-Qiong Xiang; Kai Hu; Yin-Fa Han; Yi-Xin Wang; Yi-Ran Huang; Zheng Wang
Journal:  Asian J Androl       Date:  2009-08-17       Impact factor: 3.285

10.  miR-145 and miR-143 regulate smooth muscle cell fate and plasticity.

Authors:  Kimberly R Cordes; Neil T Sheehy; Mark P White; Emily C Berry; Sarah U Morton; Alecia N Muth; Ting-Hein Lee; Joseph M Miano; Kathryn N Ivey; Deepak Srivastava
Journal:  Nature       Date:  2009-07-05       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.